11.04.2019 • NewsElaine BurridgeNovo Nordisk

Novo Nordisk Upgrades Danish Plant

Novo Nordisk Upgrades Danish Plant (c) Novo Nordisk
Novo Nordisk Upgrades Danish Plant (c) Novo Nordisk

Danish drugmaker Novo Nordisk plans to invest 650 million krone, or $98 million, to upgrade and expand facilities at its site in Kalundborg.

The plants currently manufacture a range of diabetes products but will be rebuilt to allow for future production of next-generation products. Novo Nordisk anticipates completing the project in 2020.

Michael Hallgren, Novo Nordisk’s senior vice president for production in Kalundborg, said the investment highlights the company’s ambition to continue strengthening its presence, both in Denmark and Kalundborg, which manufactures about half of the world’s insulin.

Since the turn of the millennium alone, Hallgren said, Novo Nordisk has invested more than 15 billion Danish krone ($2.26 billion) in Kalundborg, which is a cornerstone of the company's global production network. The site also produces a range of biopharmaceutical products as well as housing facilities for biotechnology company Novozymes.

In March, Novo Nordisk announced that it had reached a settlement with the US subsidiary of Israeli generics manufacturer Teva Pharmaceuticals relating to its diabetes treatment Victoza.

The agreement means that Teva cannot launch a generic version of Victoza until Dec. 22, 2023. Under certain circumstances, Teva could launch a generic version of Victoza earlier, though not before Mar. 22, 2023. If Novo Nordisk is granted six months pediatric extension for the diabetes drug, these timelines will also be extended by six months.

The agreement remains subject to review by the US Federal Trade Commission and the US Department of Justice.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.